MARGINAL ZONE LYMPHOMA (MZL)
Clinical trials for MARGINAL ZONE LYMPHOMA (MZL) explained in plain language.
Never miss a new study
Get alerted when new MARGINAL ZONE LYMPHOMA (MZL) trials appear
Sign up with your email to follow new studies for MARGINAL ZONE LYMPHOMA (MZL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a maintenance drug keep lymphoma at bay? new trial aims to find out.
Disease control Not yet recruitingThis phase 2 trial tests whether giving rituximab maintenance therapy after initial treatment with rituximab and lenalidomide (R2) can improve outcomes for people with untreated marginal zone lymphoma. About 144 patients who respond to R2 will be randomly assigned to receive ritu…
Matched conditions: MARGINAL ZONE LYMPHOMA (MZL)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 24, 2026 06:32 UTC
-
New cocktail of three drugs aims to tackle rare lymphoma
Disease control Not yet recruitingThis study tests a combination of three drugs (zanubrutinib, rituximab, and lenalidomide) as the first treatment for people with marginal zone lymphoma, a slow-growing blood cancer. The trial will enroll 50 adults aged 18-75 with advanced disease who haven't had treatment yet. Re…
Matched conditions: MARGINAL ZONE LYMPHOMA (MZL)
Phase: NA • Sponsor: Zhengzhou University • Aim: Disease control
Last updated Jun 23, 2026 11:56 UTC